文献速递血栓与止血

凝血因子X激活剂临床前研究及针对伴抑制物血友病患者的1期试验

Preclinical studies of a factor X activator and a phase 1 trial for hemophilia patients with inhibitors.
PubMed 文献 · J Thromb Haemost · 2023-02-14

STSP-0601是从圆斑蝰蛇毒中纯化的特异性凝血因子X激活剂。临床前研究显示其可剂量依赖性激活FX;1期多中心开放标签试验中,A部分16例和B部分7例伴抑制物血友病患者分别接受单次或最多6次每4小时静脉注射,未报告严重不良事件、剂量限制性毒性或血栓栓塞事件,未检测到抗药抗体。

要点

  • STSP-0601可特异性激活FX,呈剂量依赖性。
  • 1期试验中A部分8例(22.2%)、B部分18例(75.0%)不良事件与STSP-0601相关。
  • 未报告严重不良事件、剂量限制性毒性或血栓栓塞事件,未检测到抗药抗体。

核心结论

  • 临床前和临床研究显示STSP-0601具有良好的FX激活能力和良好的安全性。
  • STSP-0601可用作伴抑制物血友病患者的止血治疗。

研究设计与样本

  • 进行了体外和体内临床前研究。
  • 开展了一项1期、首次人体、多中心、开放标签试验,分为A和B两部分,在clinicaltrials.gov注册(NCT-04747964和NCT-05027230)。
  • A部分16例伴抑制物血友病患者接受单次静脉注射STSP-0601(0.01 U/kg、0.04 U/kg、0.08 U/kg、0.16 U/kg、0.32 U/kg或0.48 U/kg)。
  • B部分7例伴抑制物血友病患者接受最多6次每4小时静脉注射(0.16 U/kg)。
  • 每部分的主要终点为从基线至给药后168小时的不良事件数。

主要发现

  • 临床前研究显示STSP-0601能以剂量依赖性方式特异性激活FX。
  • A部分报告8例(22.2%)不良事件与STSP-0601相关,B部分报告18例(75.0%)不良事件与STSP-0601相关。
  • 未报告严重不良事件或剂量限制性毒性事件。
  • 未发生血栓栓塞事件。
  • 未检测到STSP-0601的抗药抗体。

关键数值与推荐

  • A部分单次给药剂量为0.01 U/kg、0.04 U/kg、0.08 U/kg、0.16 U/kg、0.32 U/kg或0.48 U/kg。
  • B部分给药方案为最多6次每4小时静脉注射0.16 U/kg。
  • 主要终点为从基线至给药后168小时的不良事件数。

临床怎么用

  • 作者认为STSP-0601可用作伴抑制物血友病患者的止血治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bleeding episodes in hemophiliacs with inhibitors are difficult to control. Staidson protein-0601 (STSP-0601), a specific factor (F)X activator purified from the venom of Daboia russelii siamensis, has been developed. OBJECTIVES: We aimed to investigate the efficacy and safety of STSP-0601 in preclinical and clinical studies. METHODS: In vitro and in vivo preclinical studies were performed. A phase 1, first-in-human, multicenter, and open-label trial was conducted. The clinical study was divided into parts A and B. Hemophiliacs with inhibitors were eligible for this study. Patients received a single intravenous injection of STSP-0601 (0.01 U/kg, 0.04 U/kg, 0.08 U/kg, 0.16 U/kg, 0.32 U/kg, or 0.48 U/kg) in part A or a maximum of 6 4-hourly injections (0.16 U/kg) in part B. The primary endpoint for each part was the number of adverse events (AEs) from baseline to 168 hours after administration. This study was registered at clinicaltrials.gov (NCT-04747964 and NCT-05027230). RESULTS: Preclinical studies showed that STSP-0601 could specifically activate FX in a dose-dependent manner. In the clinical study, 16 patients in part A and 7 patients in part B were enrolled. Eight (22.2%) AEs in part A and 18 (75.0%) AEs in part B were reported to be related to STSP-0601. Neither severe AEs nor dose-limiting toxicity events were reported. There were no thromboembolic event. The antidrug antibody of STSP-0601 was not detected. CONCLUSION: Preclinical and clinical studies showed that STSP-0601 had a good ability to activate FX and had a good safety profile. STSP-0601 could be used as a hemostatic treatment in hemophiliacs with inhibitors.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Liu W, Xue F, Fu R, et al. Preclinical studies of a factor X activator and a phase 1 trial for hemophilia patients with inhibitors. J Thromb Haemost. 2023. PMID: 36796484. doi:10.1016/j.jtha.2023.01.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。